Robert Cabrera/LinkedIn
Sep 24, 2025, 15:57
Robert Cabrera & Colleagues Developed the ELISA-Based Folate Receptor Autoantibody Assay
Robert Cabrera, Associate Professor at Baylor College of Medicine, shared on LinkedIn:
“I (we) developed the ELISA-based folate receptor autoantibody assay in 2008 based on Rothenberg’s 2004 study on neurodevelopmental risks (NTDs).
Today, 17-21 years later, folate receptor autoantibodies were mentioned in a US Presidential press conference on autism, which included Tylenol (acetaminophen) risks, and proposed treatment with reduced folate (folinic acid, leucovorin).”
Title: Autoantibodies to folate receptor during pregnancy and neural tube defect risk
Authors: Robert M Cabrera, Gary M Shaw, Johnathan L Ballard, Suzan L Carmichael, Wei Yang, Edward J Lammer, Richard H Finnell

Read more here.
Stay updated with Hemostasis Today.
acetaminophen
Autoantibody
Baylor College of Medicine
Edward J Lammer
ELISA
folinic acid
Gary M Shaw
Health
Hematology
Hemostasis
Hemostasis Today
Johnathan L Ballard
leucovorin
Medicine
neural tube defect
Neurodevelopmental Risks
Pregnancy
Richard H Finnell
Robert M Cabrera
Suzan L Carmichael
thrombosis
Tylenol
Wei Yang
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia